601211:SSEGuotai Haitong Securities Co., Ltd. Class A Analysis
Data as of 2026-03-15 - not real-time
CN¥17.94
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Guotai Haitong Securities is trading at CNY 17.94, barely above its technical support of CNY 17.87. The stock’s 20‑day SMA (18.98) lies just above the current price, indicating short‑term weakness. A low RSI of 27.2 signals that the shares are oversold, while the MACD remains bearish. Volatility over the past 30 days is moderate at 18 % and the beta of 0.21 points to minimal market‑wide swings. Fundamentally, the company posts a trailing PE of 9.86 versus an industry average of 16.35, suggesting a sizable valuation gap. Dividend yield stands at 2.4 % with a payout ratio under 25 %, supporting income appeal.
However, the balance sheet is heavily leveraged, with a debt‑to‑equity ratio near 276 %, which could constrain flexibility. Cash generation remains solid, reflected by operating cash flow of CNY 52.8 bn and a ROE of 10.4 %. The DCF model values the firm at roughly CNY 91, far above the market price, reinforcing an undervalued narrative. The company’s recent rebranding in April 2025 signals a strategic push to capture broader market share. Given the stable trading volume and low liquidity risk, the shares can be entered without significant execution concerns. Overall, the combination of deep discount, sustainable dividend, and limited price volatility makes the stock attractive for patient investors.
However, the balance sheet is heavily leveraged, with a debt‑to‑equity ratio near 276 %, which could constrain flexibility. Cash generation remains solid, reflected by operating cash flow of CNY 52.8 bn and a ROE of 10.4 %. The DCF model values the firm at roughly CNY 91, far above the market price, reinforcing an undervalued narrative. The company’s recent rebranding in April 2025 signals a strategic push to capture broader market share. Given the stable trading volume and low liquidity risk, the shares can be entered without significant execution concerns. Overall, the combination of deep discount, sustainable dividend, and limited price volatility makes the stock attractive for patient investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price near technical support
- oversold RSI indicating potential bounce
- bearish MACD confirming short‑term downtrend
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- significant PE discount to industry peers
- 2.4% dividend yield with low payout ratio
- DCF fair value far above market price
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- sustainable dividend supported by strong cash flow
- strategic position in China’s capital markets
- potential sector recovery offsetting high leverage
Key Metrics & Analysis
Financial Health
Revenue Growth128.20%
Profit Margin40.27%
P/E Ratio9.9
ROE10.43%
ROA1.81%
Debt/Equity275.98
P/B Ratio1.0
Op. Cash FlowCN¥52.8B
Industry P/E16.4
Technical Analysis
TrendNeutral
RSI27.2
SupportCN¥17.87
ResistanceCN¥20.25
MA 20CN¥18.98
MA 50CN¥19.87
MA 200CN¥19.53
MACDBearish
VolumeStable
Fear & Greed Index72.88
Valuation
Fair ValueCN¥91.42
GradeUndervalued
TypeValue
Dividend Yield2.40%
Risk Assessment
Beta0.21
Volatility18.01%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.